Neurocrine Biosciences (NBIX) Stock Forecast, Price & News

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NBIX shares.
View NBIX analyst ratings or view top-rated stocks.

17 equities research analysts have issued 1 year price objectives for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $95.00 to $150.00. On average, they expect the company's stock price to reach $125.10 in the next year. This suggests a possible upside of 34.0% from the stock's current price.
View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts.

Neurocrine Biosciences' stock was trading at $119.44 at the start of the year. Since then, NBIX shares have decreased by 21.8% and is now trading at $93.38.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our NBIX earnings forecast.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings data on Monday, February, 6th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.15 by $0.09. The company earned $412 million during the quarter, compared to the consensus estimate of $408.96 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 4.03% and a net margin of 4.00%. Neurocrine Biosciences's quarterly revenue was up 32.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.08) earnings per share.

ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco S&P MidCap Momentum ETF (XMMO), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Roc Etf (ROCI) and Virtus LifeSci Biotech Products ETF (BBP).

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.80%), State Street Corp (3.89%), Renaissance Technologies LLC (2.00%), Bank of New York Mellon Corp (1.69%), Armistice Capital LLC (1.63%) and Geode Capital Management LLC (1.47%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends.

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NBIX stock can currently be purchased for approximately $93.38.

Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $9.11 billion and generates $1.49 billion in revenue each year. The company earns $154.50 million in net income (profit) each year or $0.60 on an earnings per share basis.

The company employs 1,200 workers across the globe.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.